Arterial Occlusive Events Research Articles

Factors Associated With Impaired Kidney Function and Its Impact on Long-Term Outcome in Young Ischemic Stroke

After ischemic stroke, kidney dysfunction is linked to poor outcomes in the elderly, but regarding young patients, data are lacking. We investigated estimated glomerular filtration rate (eGFR) on admission according to the Modification of Diet in Renal Disease equation in 958 consecutive patients aged 15 to 49 years with their first-ever ischemic stroke. Logistic regression adjusted for demographics and stroke risk factors served to identify factors related to low (<60) and high (>120 mL/min/1.73 m(2)) eGFR. In the long-term follow-up (mean, 8.9±3.8 years) study, Cox proportional hazards analysis described the association between eGFR and the following end points: nonfatal/fatal ischemic stroke; composite vascular event of any stroke, myocardial infarction, revascularization/other arterial occlusive event, or vascular death; and death of any cause. Estimated GFR was normal in 809 (84.4%), low in 43 (4.5%), and high in 106 (11.1%) patients. Type 1 diabetes (OR, 18.84; 95% CI, 8.65 to 41.03), hypertension (4.29; 1.94 to 9.48), and cardiovascular disease (2.66; 1.19 to 5.96) were independently associated with low eGFR. Type 2 diabetes (3.82; 1.93 to 7.55), lower age (0.95 per year; 0.93 to 0.98), and male gender (1.74; 1.08 to 2.82) were associated with high eGFR. Both low (hazard ratio, 5.73; 95% CI, 3.54 to 9.25) and high eGFR (1.78; 1.01 to 3.14) were associated with long-term mortality when adjusted for age, gender, risk factors, stroke severity, and subtype. No independent association appeared between eGFR and vascular events. Despite their different associated risk factors in our young patient cohort, both low and high eGFR predicted long-term mortality after ischemic stroke.

Enfermedades hematológicas: desde dentro del corazón

The fundamental relationship between blood disorders and the cardiovascular system originates within multiple points of interface, ranging from the heart and its structural constituents to include heart chambers, valves, coronary arteries, coronary veins, and the cerebrovascular and peripheral vasculature. While the cellular components of circulating blood derive their primary origin from multipotent progenitor cells, plasma-based components, which include coagulation proteins, are mostly born of hepatic synthesis and endothelial cells. Here we provide a focused overview of nononcological blood disorders and their potential impact on the arterial circulatory system as common phenotypes, including myocardial infarction, ischemic stroke and peripheral arterial occlusive events. Venous thromboembolism is employed in our discussion as a clinical template. We also provide practical steps and guidance for diagnostic testing and management in routine clinical practice. Full English text available from: www.revespcardiol.org

Hematologic Diseases: From Within the Heart

The fundamental relationship between blood disorders and the cardiovascular system originates within multiple points of interface, ranging from the heart and its structural constituents to include heart chambers, valves, coronary arteries, coronary veins, and the cerebrovascular and peripheral vasculature. While the cellular components of circulating blood derive their primary origin from multipotent progenitor cells, plasma-based components, which include coagulation proteins, are mostly born of hepatic synthesis and endothelial cells. Here we provide a focused overview of nononcological blood disorders and their potential impact on the arterial circulatory system as common phenotypes, including myocardial infarction, ischemic stroke and peripheral arterial occlusive events. Venous thromboembolism is employed in our discussion as a clinical template. We also provide practical steps and guidance for diagnostic testing and management in routine clinical practice.

Novel Situations of Endothelial Injury in Stroke — Mechanisms of Stroke and Strategy of Drug Development: Protective Effects of Antiplatelet Agents Against Stroke

Stroke is the second cause of mortality worldwide, and intravenous administration of tissue plasminogen activator (t-PA) within 3 h of symptom onset is the only treatment proven effective for re-establishment of cerebral blood flow following acute ischemic stroke. However, its widespread application remains limited by its narrow therapeutic time window and the related risks of intracranial hemorrhage. On the other hand, in patients with atherothrombotic risk, antiplatelet agents are widely used to decrease the risk of occlusive arterial events. All of these drugs are used during coronary interventions and in the medical management of acute coronary syndromes. In contrast, only aspirin, cilostazol, and thienopyridine derivatives (ticlopidine and clopidogrel) are used in the long-term prevention of cerebrovascular events in patients with risk of recurrence. In this paper, we introduce recent clinical findings on antiplatelet therapies for secondary prevention after ischemic stroke and describe basic research that has focused on cerebrovascular protection by cilostazol, which has a unique pharmacological profile.

Haemorrhagic stroke during anti-platelet therapy

Drugs that inhibit platelet function are widely used to decrease the risk of occlusive arterial events in patients with atherosclerosis. There are three families of anti-platelet agents with proven clinical efficacy: (1) cyclo-oxygenase inhibitors, such as aspirin; (2) adenosine diphosphate receptor antagonists, such as the thienopyridine compounds ticlopidine and clopidogrel; and (3) glycoprotein IIb/IIIa antagonists. All these drugs are used during coronary interventions and in the medical management of acute coronary syndromes, while only aspirin and thienopyridine compounds are used in the long-term prevention of cardiovascular and cerebrovascular events in patients at risk. Despite the good risk-to-benefit ratio of anti-platelet agents, the risk of severe bleeding complications, including cerebral haemorrhage, is slightly increased, albeit to a much lesser extent than that associated with the use of other antithrombotic drugs, such as anticoagulants or thromobolytic agents. In addition, it must be noted that the increased incidence of haemorrhagic stroke is usually outweighed by a significant decrease in the incidence of ischaemic strokes. The combination of aspirin and vitamin K antagonists may be associated with the heightened risk of cerebral haemorrhage, compared to treatment with either drug alone.

373: Can pregnancy associated complications predict primary atherothrombotic occlusive vascular events in premenopausal women?

THROMBOTIC OCCLUSIVE VASCULAR EVENTS IN PREMENOPAUSAL WOMEN? GALIA ORON, YARIV YOGEV, SHLOMIT BEN-AMI, AVI BEN-HAROUSH, MOSHE HOD, JACOB BAR, Helen Schneider Hospital for Women, Rabin Medical Center, Petah Tiqwa, and Sackler Faculty of Medicine, Tel Aviv University, Obstetrics and Gynecology, Tel Aviv, Israel OBJECTIVE: Scarcity of data exists concerning the potential association between pregnancy complications as early risk factor for atherothrombotic event. The aim of this study was to determine if adverse pregnancy outcomes can be added to the list of classical risk factors for atherothrombotic occlusive vascular disease (AOVD), in young women. STUDY DESIGN: A retrospective questionnaire/case-control study. Study group included women aged 50 years with an ICD-9 diagnosis of AOVD (a documented primary cerebrovascular, myocardial, or peripheral arterial ischemic events) who were treated between 1995 to 2004. Classical risk factors for AOVD and aspects of pregnancy outcome were compared with healthy women matched individually for age, parity and body mass index. RESULTS: 1. Overall, 101 women with AOVD were identified, of them; 53 had a myocardial ischemic event, 33 a cerebrovascular event, and 15 a peripheral ischemic arterial event. 2. On multivariate analysis, in addition to the known risk factors for AOVD (diabetes, hypertension, dyslipidemia and family history of vascular disease) intrauterine growth restriction was found to be an independent risk factor for development of AOVD (O.R 8.41, 95% C.I 2.36-29.9, p 0.001). 3. Women with more than one of the following pregnancy complication (GDM, PET, spontaneous preterm delivery, placental abruption, or fetal loss) were at increased risk for more than one arterial occlusive event (O.R 13.71, 95% C.I 1.56-120.39, p 0.02). CONCLUSION: Intrauterine growth restriction and multiple pregnancy complications are independent, early risk factor for subsequent AOVD in pre-menopausal women

Thrombophilia–hypofibrinolysis and atherothrombotic cardiovascular disease ≤ age 45 years

Thrombophilia-hypofibrinolysis may play an important role in rare premature (< or = age 45 years) arterial occlusive events in atherothrombotic cardiovascular (ATCVD) disease, particularly in normolipidemic patients. Whether thrombophilia-hypofibrinolysis contributed to ATCVD < or = age 45 years was assessed in 78 men and 40 women with 230 ATCVD events (myocardial infarction (MI) [n = 60], coronary artery bypass graft [CABG, n = 33], angioplasty [n = 52], chronic angina [n = 41], ischemic stroke [n = 11], transient ischemic attack [TIA, n = 24], claudication [n = 9]). Cases were compared with healthy normal adult controls (44 men and 76 women). In men, the Factor V Leiden mutation was present in 6/63 (10%) cases versus 0/44 (0%) controls (P = 0.042), Factor VIII was high (>150%) in 16/60 (27%) cases versus 1/42 (2%) controls (P = 0.001), Factor XI was high (>150%) in 9/57 (16%) cases versus 0/42 (0%) controls (P = 0.009), and plasminogen activator inhibitor activity (PAI-Fx) was high (>21.1 U/mL) in 15/63 (24%) cases versus 3/43 (7%) controls (P = 0.023). In women, protein C was low (<73%) in 4/26 (15%) cases versus 0/74 (0%) controls (P = 0.004), and free protein S was low (<66%) in 5/27 (19%) cases versus 2/74 (3%) controls (P = 0.014). In women, Factor XI was high (>150%) in 3/27 (11%) cases versus 1/74 (1%) controls (P = 0.057), and the lupus anticoagulant was present in 9/32 (28%) cases versus 2/51 (4%) controls (P = 0.002). In patients with ATCVD < or = age 45 years, thrombophilias (Factor V Leiden, Factor VIII, Factor XI, protein C and S deficiency, lupus anticoagulant) and hypofibrinolysis (PAI-Fx, Lp[a]) may promote arterial thrombosis, which is synergistic with atherosclerotic endothelial injury.

Laboratory detection of 'aspirin resistance': what test should we use (if any)?

Aspirin is widely used to decrease the risk of occlusive arterial events in patients at risk. It irreversibly inhibits the cyclooxygenase-1 (COX-1)-dependent synthesis of thromboxane A2 (TxA2), which is essential for the full aggregation response of platelets. In the last years, the issue of ‘aspirin resistance’ has been emphasized in the medical literature.1–4 Despite several studies published on this subject, its definition, diagnosis, prevalence, causes, and clinical consequences are still uncertain.1 The term ‘resistance’ to a drug should be used when a drug is unable to hit its pharmacological target, due to inability to reach it (as a consequence of reduced bioavailability, in vivo inactivation, negative interaction with other substances) or to alterations of the target.1 Based on this definition, the term ‘resistance’ to aspirin should be limited to situations in which aspirin is unable to inhibit COX-1-dependent TxA2 production (and, consequently, TxA2-dependent platelet functions). ### ‘Aspirin resistance’ vs. ‘treatment failure’ If the anti-thrombotic effects of aspirin are dependent on inhibition of COX-1, one would expect that patients in whom aspirin does not inhibit COX-1 do not benefit from the protection that this drug provides and are exposed to high risk of atherothrombotic events. However, it is incorrect to consider ‘resistant’ to aspirin all those patients who experience atherothrombotic events while on treatment. This phenomenon has been named ‘clinical resistance’, but it should be more properly termed ‘treatment failure’.1,2 It can be observed with any kind of treatment and is expected to be particularly frequent for drugs, like aspirin and all other anti-thrombotic agents, that are used to prevent multi-factorial diseases, such as those associated with vascular occlusion, independently of their efficacy to hit their pharmacological targets. ### ‘Aspirin resistance’ vs. ‘high on-treatment residual platelet reactivity’ In consideration of the importance of TxA2 pathway in platelet activation, one would expect that … Corresponding author. Tel: +39 (0) 250323095; fax: +39 (0) 250323095. E-mail address : marco.cattaneo{at}unimi.it

Ischemia and infarction of the small bowel and colon: spectrum of imaging findings

Mesenteric ischemia presents as an abdominal emergency due to decreased intestinal blood flow secondary to mesenteric arterial vascular hypoperfusion, occlusion, or impaired venous drainage [1]. The small bowel or colon may be involved. Distinction between intestinal ischemia and infarction sometimes is not considered adequately in the interpretative process: the ischemia may be a transient and a totally reversible event, whereas infarction may be one of the possible consequences that requires surgical or interventional management. Despite continuing advances in imaging and surgical techniques, early detection of intestinal ischemia before infarction develops remains difficult [2]. Early diagnosis is important to improve survival rates [2, 3]; in most cases of late or missed diagnosis, mortality rate from intestinal infarction is very high, from 60% to 90% [4–6]. Prognosis of an ischemic intestinal insult depends upon clinical factors, such as its acuteness, duration and severity, the presence of collateral vascular circulation, the response of the mesenteric vascular branches and intestinal wall to the injury [7], extent of intestinal involvement, and the timeliness of diagnosis and intervention. From a phase in which the intestinal vascular injury may be suspected and the imaging findings of ischemia noted, the severity of mural damage may proceed rapidly to infarction with dire consequences. Differences in bowel wall findings may be appreciable between small bowel arterial and venous infarctions [8–10]. Radiologic descriptions of intestinal ischemia and infarction reported in the literature are rich [10–13] but not pathognomonic. Currently, there is no report of a direct correlation between bowel wall findings and a confirmed diagnosis of ischemia or infarction. Most literature on this topic is characterized by nonhomogeneous material and methodology of study. Some parameters regarding the timing of imaging in which studies are performed, intravenous and/or oral contrast medium administration, dynamics of the acute vascular injury, and the different etiologies (superior or inferior venous or arterial mesenteric vessels, occlusive or nonocclusive event) are sometimes difficult to summarize in a comparative classification. However, diagnostic imaging may play a pivotal role in the detection of the degree and severity of intestinal ischemia and assessment for evidence of infarction. In the following sections, imaging findings (wall thickness and enhancement, caliber of intestinal loops, presence of air-fluid levels, intestinal peristalsis, mesenteric arterial and venous vessel viabilities, mural and/or portal/mesenteric pneumatosis) from different method of study (abdominal plain film, sonography [US], and computed tomography [CT]) will be correlated to various phases of intestinal changes from ischemia and infarction due to mesenteric vessels hypoperfusion or occlusion based on experience in our institutions.

The platelet P2Y receptors as targets for new antithrombotic drugs

Drugs that inhibit platelet function are widely used to decrease the risk of occlusive arterial events in patients with atherosclerosis. There are three families of anti-aggregating agents with proven clinical efficacy: (i) cyclooxygenase inhibitors, such as aspirin; (ii) ADP receptor antagonists, such as the thienopyridine compounds ticlopidine and clopidogrel; (iii) glycoprotein IIb/IIIa antagonists. All these drugs are used during coronary interventions and in the medical management of acute coronary syndromes, while only aspirin and the thienopyridine compounds are used in long-term prevention of cardiovascular and cerebrovascular events in patients at risk.

Prevention and treatment of arterial thrombosis in pregnancy.

In the last few years there has been a marked increase in the recognition of patients who are potentially at risk of arterial occlusive events during pregnancy. This includes patients with a previous history of arterial occlusion such as myocardial infarction and stroke, patients known to carry acquired or inherited thrombotic risk factors including sickle cell and myeloproliferative disorders, and patients with prosthetic heart valves. This review details the management options for prevention of arterial occlusions in these at-risk patients and outlines potential management strategies for arterial occlusions occurring during pregnancy.

Echocardiographic Findings of Patients With Retinal Ischemia or Embolism

A potential source of emboli is not detected in more than 50% of patients with retinal arterial occlusive events. Echocardiographic studies are not always included in the diagnostic workup of these patients. The authors studied the diagnostic yield of transthoracic (TTE) and/or transesophageal (TEE) echocardiography in identifying potential sources of emboli in patients with retinal ischemia or embolism. In a prospective study, 73 consecutive patients with clinically diagnosed retinal ischemia or embolism received a standardized diagnostic workup including retinal photography, echocardiography, and imaging studies of the internal carotid arteries. TTE was performed in 83.6% of patients, TEE was performed in 5.5% of patients, and both TTE and TEE were performed in 11.0% of patients. Ophthalmological diagnoses consisted of amaurosis fugax (n = 28), asymptomatic cholesterol embolism to the retina (n = 34), and branch or central retinal artery occlusion (n = 11). Echocardiography identified a potential cardiac or proximal aortic source for embolism in 16 of 73 (21.9%) patients, including 8 who also had either atrial fibrillation or internal carotid artery stenosis of more than 50% on the side of interest. Thus, 8 of 73 (11.0%) patients had lesions detected only by echocardiography. The most commonly identified lesions were proximal aortic plaque of more than 4 mm thickness (n = 7, 9.6%) and left ventricular ejection fraction of less than 30% (n = 6, 8.2%). TEE was particularly helpful in identifying prominent aortic plaques. Echocardiography frequently identifies lesions of the heart or aortic arch that can act as potential sources for retinal ischemia or embolism. Further studies are needed to evaluate the prognostic and therapeutic relevance of these findings.

High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.

To compare the incidence of cardiovascular (CV) events in persons with rheumatoid arthritis (RA) with that in people from the general population, adjusting for traditional CV risk factors. Two hundred thirty-six consecutive patients with RA were assessed for the 1-year occurrence of 1) CV-related hospitalizations, including myocardial infarction, stroke or other arterial occlusive events, or arterial revascularization procedures, or 2) CV deaths. Both outcomes were ascertained by medical records or death certificates. For comparison, we used CV events that occurred during an 8-year period among participants in an epidemiologic study of atherosclerosis and CV disease who were ages 25-65 years at study entry. We calculated the age- and sex-stratified incidence rate ratio (IRR) of CV events between the 2 cohorts and used Poisson regression to adjust for age, sex, smoking status, diabetes mellitus, hypercholesterolemia, systolic blood pressure, and body mass index. Of the 236 RA patients, 234 were observed for 252 patient-years, during which 15 CV events occurred. Of these, 7 incident events occurred during the 204 patient-years contributed by patients ages 25-65 years, for an incidence of 3.43 per 100 patient-years. In the comparison cohort, 4,635 community-dwelling persons were followed up for 33,881 person-years, during which 200 new events occurred, for an incidence of 0.59 per 100 person-years. The age- and sex-adjusted IRR of incident CV events associated with RA was 3.96 (95% confidence interval [95% CI] 1.86-8.43). After adjusting for CV risk factors using Poisson regression, the IRR decreased slightly, to 3.17 (95% CI 1.33-6.36). The increased incidence of CV events in RA patients is independent of traditional CV risk factors. This suggests that additional mechanisms are responsible for CV disease in RA. Physicians who provide care to individuals with RA should be aware of their increased risk of CV events and implement appropriate diagnostic and therapeutic measures.

Arterial occlusive events during chemotherapy for germ cell cancer

During four courses of chemotherapy for a disseminated testicular seminoma a 30-year-old man developed three arterial occlusive events and one silent myocardial infarction. The events occurred approximately 10 days after the start of each chemotherapy course. During chemotherapy suggested pathogenetic factors were monitored without observing any significant abnormality. After completion of chemotherapy the patient remained in a complete remission and free of new thromboembolic events. A review of possible pathogenetic factors is given.

High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors

To compare the incidence of cardiovascular (CV) events in persons with rheumatoid arthritis (RA) with that in people from the general population, adjusting for traditional CV risk factors.Two hundred thirty-six consecutive patients with RA were assessed for the 1-year occurrence of 1) CV-related hospitalizations, including myocardial infarction, stroke or other arterial occlusive events, or arterial revascularization procedures, or 2) CV deaths. Both outcomes were ascertained by medical records or death certificates. For comparison, we used CV events that occurred during an 8-year period among participants in an epidemiologic study of atherosclerosis and CV disease who were ages 25-65 years at study entry. We calculated the age- and sex-stratified incidence rate ratio (IRR) of CV events between the 2 cohorts and used Poisson regression to adjust for age, sex, smoking status, diabetes mellitus, hypercholesterolemia, systolic blood pressure, and body mass index.Of the 236 RA patients, 234 were observed for 252 patient-years, during which 15 CV events occurred. Of these, 7 incident events occurred during the 204 patient-years contributed by patients ages 25-65 years, for an incidence of 3.43 per 100 patient-years. In the comparison cohort, 4,635 community-dwelling persons were followed up for 33,881 person-years, during which 200 new events occurred, for an incidence of 0.59 per 100 person-years. The age- and sex-adjusted IRR of incident CV events associated with RA was 3.96 (95% confidence interval [95% CI] 1.86-8.43). After adjusting for CV risk factors using Poisson regression, the IRR decreased slightly, to 3.17 (95% CI 1.33-6.36).The increased incidence of CV events in RA patients is independent of traditional CV risk factors. This suggests that additional mechanisms are responsible for CV disease in RA. Physicians who provide care to individuals with RA should be aware of their increased risk of CV events and implement appropriate diagnostic and therapeutic measures.

Factors Affecting the Surgical Management of Infective Endocarditis

Congestive heart failure and septic embolism complicate the clinical course of patients with infective endocarditis (IE). This study reviews the clinical records of patients with systemic disease secondary to IE and stratifies their disease severity according to individual risk factors and medical, and surgical interventions. The hospital records of all patients presenting to our institution from 1992 through 1997 with heart valve destruction secondary to IE were reviewed. Ten patients with hemodynamically significant valve lesions were included in this study: seven with aortic valve disease and two with mitral valve disease, and one with combined aortic and mitral valve lesions. All were diagnosed by echocardiogram. All ten patients experienced systemic septic arterial emboli: four intracranial lesions, four visceral lesions, and three extremity arterial occlusive events. Two patients required peripheral arterial repair. Cultures revealed infection secondary to Staphylococcus aureus in five, Streptococcus species in three, Coxiella species in one, and an unidentified organism in one patient. Seven patients underwent valve replacement. Three patients died from their disease processes. Statistical significance was established by Wilcoxon rank analysis with a two-tailed P < 0.05. Patients with IE secondary to staphylococcal infections suffered a more acute and virulent disease process (P = 0.04), with a 40 per cent mortality rate in the first 48 hours. There was no increased incidence of embolization associated with longer duration of symptoms (P = 0.32). Surgical repair conferred improved clinical outcome as compared with no surgical intervention (P = 0.03). Improved patient outcome was associated with nonstaphylococcal infection (P = 0.02), and a successful initial antibiotic regimen (P = 0.03). Peripheral arterial repair was successful in both cases.

Role of Echocardiography in Systemic Arterial Embolism: A Review with Recommendations

The ability of echocardiography to diagnose sources of embolism and the role of the examination in the prediction of thromboembolism are reviewed. In addition, the yield of transthoracic (TTE) and transoesophageal echocardiography (TEE) is analysed in patients with suspected embolism and guidelines are proposed for performing echocardiography in this setting. In general, echocardiography is reliable for diagnosing sources of embolism and this applies in particular to TEE in the case of atrial, valvular, and aortic abnormalities. However, the method is useful for predicting embolism in a few cases only. There is a substantial risk in the event of mobile or protruding thrombi, but screening for these and other markers of thromboembolism seems to be unproductive in most groups of risk patients. Yet, in the presence of atrial fibrillation, echocardiography may be helpful in defining patients with an otherwise normal heart and low risk of embolism - and in defining the relatively rare patient with a clinically low-risk profile but moderate-to-severe left ventricular systolic dysfunction and a high risk of embolism. TEE-guided conversion of atrial fibrillation without weeks of preceding anticoagulation may prove useful, after further investigation. The risk of embolism in relation to the size and mobility of valvular vegetations has remained controversial. In patients with suspected recent embolism, TTE results in less than 5% new therapeutic consequences. In those with a normal TTE, the yield of TEE seems to be equally low. We therefore recommend a selective strategy: TTE and TEE can be omitted when a cardiac source of embolism appears from the clinical setting and in most patients with an obvious predisposition to cerebrovascular disease. However, in the latter cases TTE should be performed if indicated by the clinical situation, e.g. in the presence of fever and murmur. TTE is also recommended when there are no obvious markers of primary vascular disease. To preclude very rare sources of embolism (e.g. atrial thrombi despite sinus rhythm), supplementary TEE is recommended in younger patients in whom primary vascular disease is very unlikely. The diagnosis by TEE of common conditions such as atrial septal aneurysms and patent foramen ovale cannot, however, be taken as proof of the mechanism of a systemic arterial occlusive event; thus it is difficult to change therapy on the basis of such diagnoses.

Histological appearance of the intra-osseous vessels of the femoral head in aseptic osteonecrosis of the hip, with or without antiphospholipid antibodies.

It has been suggested that in some patients non-traumatic aseptic osteonecrosis of the hip (AOH) could be the result of the intra-osseous thrombosis. Antiphospholipid antibodies (APL) have been associated with venous and arterial occlusive events and the association between AOH and APL syndrome has been reported. To compare bone vessels of the femoral head in patients operated on for AOH with or without APL. Twenty patients (mean age 47 yrs) with AOH were included: in eight patients APL (IgG-ELISA) were negative (< 8 GPL units), in nine patients APL were doubtful (8-15 GPL units), and in three patients APL were positive (> 15 GPL units). Bone vessels were examined: arteriosclerotic lesions, i.e. fibrosis or thickening of the media and rupture of the internal elastic lamina, thrombosis or vasculitis were sought in the femoral heads after total hip replacement or core decompression. Bone vessel lesions were the same in the three groups.

Economic implications of thrombolysis or operation as the initial treatment modality in acute peripheral arterial occlusion

Thrombolytic agents have been used to treat arterial occlusion for almost 40 years. Recently, an investigation of the costs associated with two treatment options for acute peripheral arterial occlusions, thrombolysis and surgical intervention, was completed. The availability of hospital cost data for patients enrolled in the thrombolytic and operative treatment groups provided a basis with which to accurately assess the financial impact of the different treatment strategies, both from a purely financial standpoint and in relation to outcome. The patient base was composed of 114 patients with acute limb ischemia of less than 7 days' duration. The patients were randomly assigned to receive urokinase (n = 57) or to undergo an operation (n = 57) as the initial therapeutic intervention. Patients in the thrombolytic group underwent standard intraarterial diagnostic arteriography, and patients with embolic events, in whom complete lysis of all embolic and propagated thrombotic material was achieved, were subsequently treated with heparin and long-term warfarin (Coumadin) therapy. The economic analysis was undertaken after the completion of the trial. Statistical comparisons between groups were made with the Student t test for continuous, normally distributed data. Mortality and limb salvage rates were calculated from Kaplan-Meier curves, appropriate for the censored nature of the data. The total treatment costs did not differ significantly between the two treatment groups ($22,171 +/- $4,959 in the thrombolytic group and $19,775 +/- $5,253 in the operative group). The total hospital charges were similar between the two groups. Overall, the total charges were remarkably similar between the two treatment groups, averaging $40,823 +/- $8,764 in the thrombolytic group and $41,930 +/- $10,398 in the operative group. An economic analysis of the data confirmed that the total economic impact of thrombolysis approximated that of initial operative therapy. The improved clinical outcome in patients treated with thrombolysis suggests that this modality may be appropriate as the initial therapeutic intervention in the select group of patients seen within the first few hours of an acute peripheral arterial occlusive event.

Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer

Twenty-one consecutive patients with testicular cancer treated with bleomycin, vinblastine, and cisplatin (PVB) were evaluated for acute vascular ischaemic events during chemotherapy. Angina pectoris occurred in 8/21 (38%) patients, a median 5.6 weeks after initiation of chemotherapy and persisted for 2-7 days. Raynaud's phenomenon was detected in seven (33%) subjects, transient ischaemia of the toes was found in six (29%) patients, one patient complained of migraine, but none had major cerebrovascular accidents. Patients with and without angina pectoris and/or Raynaud's phenomenon did not differ in respect of age, histology of tumor or medication. Ischaemia occurred at any time during the course of chemotherapy. No correlation was found between dosage of drugs and time of onset of ischaemic reactions. However, arterial occlusive event is a frequent and common toxicity and a result of treatment with PVB.